Cytokinetics, Incorporated (CYTK)
| Market Cap | 9.57B +100.4% |
| Revenue (ttm) | 105.82M +450.6% |
| Net Income | -829.61M |
| EPS | -6.84 |
| Shares Out | 124.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,791,775 |
| Open | 74.51 |
| Previous Close | 74.29 |
| Day's Range | 74.51 - 78.80 |
| 52-Week Range | 29.31 - 80.20 |
| Beta | 0.38 |
| Analysts | Strong Buy |
| Price Target | 93.95 (+22.16%) |
| Earnings Date | May 5, 2026 |
About CYTK
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h... [Read more]
Financial Performance
In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month stock price target is $93.95, which is an increase of 22.16% from the latest price.
News
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million
SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its commo...
Cytokinetics price target raised to $105 from $95 at Wells Fargo
Wells Fargo raised the firm’s price target on Cytokinetics (CYTK) to $105 from $95 and keeps an Overweight rating on the shares. The firm notes Q1 Myqorzo sales suggest strong
Cytokinetics 9.8M share Secondary priced at $71.00
The deal size was increased to $700M in common stock from $650M in common stock. Morgan Stanley, Goldman Sachs, JPMorgan and Jefferies acted as joint book running managers for the
Cytokinetics price target raised to $108 from $98 at Stifel
Stifel raised the firm’s price target on Cytokinetics (CYTK) to $108 from $98 and keeps a Buy rating on the shares.
Cytokinetics price target raised to $119 from $101 at RBC Capital
RBC Capital raised the firm’s price target on Cytokinetics (CYTK) to $119 from $101 and keeps an Outperform rating on the shares after its Q1 results. Investors have not yet
Cytokinetics price target raised to $103 from $90 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cytokinetics (CYTK) to $103 from $90 and keeps an Overweight rating on the shares. The firm sees the topline results from Cytokinetics’
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common...
Cytokinetics Earnings Call Transcript: Q1 2026
MYQORZO's U.S. launch exceeded expectations with $4.8M in Q1 revenue and strong prescriber uptake. Positive phase III results for aficamten in NHCM and European approval of MYQORZO position the company for global expansion.
Cytokinetics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 milli...
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
U.S. Launch of MYQORZO ® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maxim...
Cytokinetics price target raised to $106 from $92 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Cytokinetics (CYTK) to $106 from $92 and keeps a Buy rating on the shares. Positive data from ACACIA-HCM, the pivotal
Cytokinetics report ‘arguably a best-case scenario’ for Edgewise, says Stifel
Stifel notes that Cytokinetics (CYTK) announced ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, met both dual prim...
Cytokinetics Phase 3 data bodes well for Edgewise, says Raymond James
Cytokinetics (CYTK) reported statistically positive Phase 3 ACACIA results for aficamten in non-obstructive hypertrophic cardiomyopathy, an outcome that bodes well for Edgewise Therapeutics (EWTX), as...
This Is Why Cytokinetics Stock (CYTK) Soared Today
Cytokinetics stock was up on Tuesday after a Phase 3 clinical trial met its primary endpoints.
Cytokinetics reports ACACIA-HCM trial met both primary endpoints
Cytokinetics (CYTK) announced topline results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. ACACIA-HCM met ...
Cytokinetics Transcript: Study result
The phase III ACACIA-HCM trial of aficamten in non-obstructive HCM met both primary endpoints, showing significant and clinically meaningful improvements in symptoms and exercise capacity versus placebo, with a favorable safety profile and consistent efficacy across patient groups. Full data will be presented at future medical meetings.
Cytokinetics heart disease drug meets main goals in late-stage study
Cytokinetics said on Tuesday its experimental drug to treat a type of heart disease met the main goals in a late-stage trial.
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key Secondary Endpoints
Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announce...
Cytokinetics call volume above normal and directionally bullish
Bullish option flow detected in Cytokinetics (CYTK) with 3,312 calls trading, 1.7x expected, and implied vol increasing almost 9 points to 174.29%. May-26 95 calls and Jun-26 85 calls are
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Co...
Cytokinetics to Announce First Quarter Results on May 5, 2026
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2026 it granted stock options to purchase an aggregate of 49...
Cytokinetics put volume heavy and directionally bearish
Bearish flow noted in Cytokinetics (CYTK) with 1,256 puts trading, or 1.6x expected. Most active are Jun-26 55 puts and May-26 35 puts, with total volume in those strikes near
Cytokinetics Transcript: 25th Annual Needham Virtual Healthcare Conference
MYQORZO launched in the US in early 2026 with rapid uptake, strong differentiation, and Medicare access nearing parity with competitors. European launch begins in Germany, with broader rollout planned. Key clinical catalysts include ACACIA-HCM phase III data in Q2 and ongoing pipeline expansion.